ArcherDX and UCL to Present Data from their Collaboration at the 2020 AACR Virtual Annual Meeting BOULDER, Colo., April 15, 2020 /PRNewswire/ — ArcherDX, Inc., […]

ArcherDX Receives Approval for Archer®MET Companion Diagnostic for TEPMETKO® (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan BOULDER, Colo., March 25, 2020/PRNewswire/ — ArcherDX, […]

ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, […]

ArcherDX to Present at 38th Annual J.P. Morgan Healthcare Conference BOULDER, Colo., Jan. 8, 2020 /PRNewswire/ — ArcherDX, Inc., a molecular diagnostics company dedicated to […]

ArcherDX Appoints Mark Massaro Chief Financial Officer BOULDER, Colo., Jan. 7, 2020 /PRNewswire/ — ArcherDX, Inc., a molecular diagnostics company developing breakthrough solutions to advance […]

ArcherDX Announces Close of $55 Million Series C Financing Proceeds to Support Registration and Launch of STRATAFIDEâ„¢ Pan-Solid Tumor Companion Diagnostic (CDx) and Development of […]

ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests Partnership Expands Physician Access to Clinical Testing that May be Performed in Local Laboratories for […]

ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration Enabling Genomically Defined Treatments for Underserved Cancers BOULDER, Colo., July 8, 2019 /PRNewswire/ — ArcherDX, Inc., […]